SP
NBIX icon

SIH Partners’s Neurocrine Biosciences NBIX Stock Holding History

SIH Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$406K Hold
3,083
– – 0.01% 230
2025
Q4 		$437K Hold
3,083
– – 0.01% 167
2025
Q3 		$433K Hold
3,083
– – 0.01% 171
2025
Q2 		$388K Sell
3,083
-4,428
-59% -$508K 0.01% 130
2025
Q1 		$831K Buy
+7,511
New +$952K 0.03% 134

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SIH Partners's NBIX Position: Q1 2026 in Review

SIH Partners held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 3,083 shares worth $406K. The position accounts for 0.01% of the portfolio, ranked #230.

SIH Partners first reported a position in NBIX in Q1 2025 and has held it in 5 quarters since. The position peaked at $831K in Q1 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • SIH Partners held 3,083 shares of Neurocrine Biosciences worth $406K as of Q1 2026.
  • SIH Partners left its Neurocrine Biosciences share count unchanged in Q1 2026.
  • Neurocrine Biosciences made up 0.01% of SIH Partners's portfolio in Q1 2026, its #230 holding.
  • SIH Partners first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 5 quarters since.
  • SIH Partners's Neurocrine Biosciences position peaked at $831K in Q1 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on SIH Partners's 13F filing for Q1 2026, filed 15 May 2026.